Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan Eyes FY2023 Launch of Pandemic Response Agency
The Japanese government plans to set up a new agency to oversee pandemic responses in FY2023, which starts in April 2023, by submitting a relevant bill to the next ordinary Diet session to be convened early next year, according to…
To read the full story
Related Article
- Japan Diet Ends Ordinary Session, All 7 MHLW-Submitted Bills Enacted
June 22, 2023
- Japan’s Diet Enacts Bill to Establish Pandemic Response Agency
April 24, 2023
- Japan Cabinet OKs Bill to Create Pandemic Response Agency
February 8, 2023
- MHLW Planning to Submit 6 Bills in Ordinary Diet Session, “Japan CDC” Plan Included
January 13, 2023
- Deliberations Underway for Transfer of Some MHLW Functions to Boost Pandemic Responses: Vice Health Minister
August 10, 2022
- Govt Officially OKs Launch of Pandemic Response Agency, Japan CDC
June 20, 2022
- Kishida Officially Unveils Plan to Form Pandemic Response Agency, Japan CDC
June 16, 2022
- Japan to Launch New Agency for Pandemic Responses, Eyes MHLW Rejig
June 15, 2022
REGULATORY
- MFN Now a Factor in Japan’s Drug Pricing Debate: New Pharma Policy Chief
September 11, 2026
- MHLW to Weigh Survey Data, Past Approach for FY2027 Revision: Official
September 10, 2026
- Chuikyo Reps Back Greater Transparency, but Lean toward Broader CEA Price Cuts
September 10, 2026
- OTC-Like Drug Charge Gets Prescription Field; No Double Charge with LLP Rule
September 10, 2026
- Defense Chief Seeks MHLW Help Securing Drugs for SDF
September 9, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…